Semaglutide for cardiovascular risk reduction in obesity

In March 2024, the FDA approved an expanded indication for semaglutide 2.4 mg (Wegovy) to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight. This lineage traces backward from that approval through the science that made it possible.

Draft scaffold. Content below contains verified endpoint facts and lineage structure. Sections marked [NEEDS REVIEW] require source confirmation before publication.

Endpoint

FDA label expansion based on the SELECT trial

The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) randomized over 17,000 adults with established cardiovascular disease and BMI ≥27 to semaglutide 2.4 mg or placebo. The primary endpoint was time to first occurrence of a major adverse cardiovascular event (MACE): cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke.

Semaglutide reduced MACE by 20% (hazard ratio 0.80, 95% CI 0.72–0.90). Based on these results, the FDA approved the cardiovascular risk reduction indication in March 2024.

At a glance

The endpoint: FDA approval of cardiovascular risk reduction indication for Wegovy (semaglutide 2.4 mg), March 2024
The trial: SELECT (NCT03574597), 17,604 participants, median follow-up 39.8 months
The drug: Semaglutide 2.4 mg subcutaneous weekly injection, GLP-1 receptor agonist
The disease: Adults with established cardiovascular disease and obesity or overweight (BMI ≥27)
Why it took decades: GLP-1 had to be discovered as a hormone, developed as a drug, proven for weight loss, and then tested in a dedicated cardiovascular outcomes trial

Reverse-lineage scaffold

What had to happen first

Incretin biology discovered

The observation that oral glucose produces greater insulin release than intravenous glucose (the incretin effect) led to the identification of gut-derived hormones including GLP-1. [NEEDS REVIEW: exact timeline and key labs]

GLP-1 identified and characterized

GLP-1 was identified as a product of the proglucagon gene, secreted by intestinal L-cells. Its insulin-stimulating, appetite-suppressing, and gastric-emptying effects were characterized. [NEEDS REVIEW: key researchers, 1980s–1990s timeline]

GLP-1 made into a drug

Native GLP-1 is degraded within minutes by DPP-4. Modifications (acylation, albumin binding) extended its half-life enough for weekly dosing. Novo Nordisk developed liraglutide, then semaglutide. [NEEDS REVIEW: specific chemistry milestones]

Diabetes efficacy established

Semaglutide was first approved for type 2 diabetes (Ozempic, 2017). GLP-1 agonists became established as a diabetes drug class. [Verified: FDA approval 2017]

Weight loss efficacy established

Higher-dose semaglutide (2.4 mg) was tested in the STEP trials for chronic weight management. FDA approved Wegovy for obesity in June 2021. [Verified: FDA approval 2021]

Cardiovascular outcomes trial designed

SELECT was designed to test whether semaglutide-mediated weight loss (or other mechanisms) reduces cardiovascular events in adults with obesity and established CVD. [Verified: NCT03574597, enrolled 2018–2021]

SELECT trial results

20% reduction in MACE. First GLP-1 agonist to demonstrate cardiovascular benefit in a population selected for obesity/overweight rather than diabetes. [Verified: Lincoff et al., NEJM 2023]

FDA cardiovascular indication

FDA approved expanded Wegovy label for cardiovascular risk reduction, March 2024. [Verified: FDA approval]

Discovery timeline

[TO BE BUILT]

Full categorized timeline (Milestone / Branch point / Detour / Convergence) to be developed after source review. Key events to include: incretin effect observation, GLP-1 identification, DPP-4 degradation problem, acylation chemistry, liraglutide development, semaglutide development, diabetes approvals, STEP trials, SELECT trial, cardiovascular indication.

Known vs. unknown

What the evidence says and what remains open

Established

Semaglutide 2.4 mg reduces MACE by 20% in adults with CVD and obesity/overweight
The SELECT trial enrolled 17,604 participants with median 39.8 months follow-up
FDA approved the cardiovascular risk reduction indication (March 2024)
The drug was already approved for weight management (2021) and type 2 diabetes (2017)

Not yet known

Whether the cardiovascular benefit is driven by weight loss, direct vascular effects, or both [NEEDS REVIEW]
Long-term cardiovascular outcomes beyond trial duration
Whether benefit extends to patients without established CVD
Durability of effect if treatment is discontinued

Sources and confidence

Confidence flag

High for endpoint facts (FDA approval, SELECT trial results). Moderate for reverse-lineage details (incretin biology history needs source confirmation for specific labs and dates).

Source links

ClinicalTrials.gov NCT03574597 — SELECT trial record
Lincoff et al., NEJM 2023 — primary SELECT results
FDA approval announcement, March 2024
[TODO: Holst, Physiol Rev 2007 — GLP-1 biology review]
[TODO: Knudsen et al. — semaglutide chemistry]